Chief Executive Officer
Patrick Fourteau served as President and Chief Executive Officer of Shionogi from 2008 until 2010. Prior to the acquisition of Sciele by Shionogi and Co. Ltd., Mr. Fourteau served as President and CEO of Sciele Pharma from 2003 until 2008 and served on the board of directors of Sciele from 2004 until 2008. He is a seasoned pharmaceutical industry executive having over 30 years of healthcare industry experience, with particular expertise in executing sales strategies for pharmaceutical products. Mr. Fourteau served as President of Worldwide Sales of inVentiv Health, Inc. from 2000 to 2002, President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company. He serves on the Board of Insys Therapeutics. Mr. Fourteau earned his B.A. and M.A. in Mathematics from the University of California, Berkeley and an MBA from Harvard University.
Harry H. Penner, Jr.
Mr. Penner is co-founder, Chairman and CEO of the company. He has 30 years of management experience in the pharmaceutical and biotechnology sectors. He previously founded and co-founded six other biotechnology companies, including Rib-X Pharmaceuticals, Inc., Marinus Pharmaceuticals, Inc., RxGen, Inc., MAKScientific, LLC, RHEI Pharmaceuticals, Inc. and Affinimark Technologies, Inc. He has served as Chairman and Chief Executive Officer of Nascent BioScience, Inc. since September 2001 and most recently served as the Chairman and Chief Executive Officer of Marinus Pharmaceuticals. From 1993 to 2001, he was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation, a publicly-traded biotechnology company. Previously, he served as Executive Vice President of Novo Nordisk A/S and President of Novo Nordisk of North America, Inc. from 1988 to 1993. From 1985 to 1988, he was Executive Vice President and General Counsel of Novo Nordisk A/S. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. from New York University and has completed senior management programs at Stanford.
Nancy C. Motola, Ph.D., R.A.C.
Vice President of Regulatory Affairs
Dr. Motola is the Vice President, Regulatory Affairs, of NHP. She is also the founder and Principal Consultant of her sole proprietorship, Pharma Regulatory Connection, a full service Regulatory Affairs consultancy firm to the Pharmaceutical Industry since 2009. She was previously Senior Vice President, Regulatory Affairs, at Rib-X Pharmaceuticals. from 2008 to 2010. From 1998 until 2008 she was Vice President and Senior Vice President, Regulatory Affairs and Quality at Alexion Pharmaceuticals, Inc., where she was responsible for the US and EU approvals of Soliris (eculizumab), the company's first product. Prior to Alexion, she spent 11 years in Regulatory Affairs positions of increasing responsibility, including Bayer Corp., where she obtained NDA approvals of Baycol, Adalat CC and Nisocor; Abbott Laboratories, where she had regulatory responsibility for the Depakote (divalproex sodium) product line; and E.R. Squibb and Sons, Inc., where she also spent five years as a Research Investigator in Chemical Development. She is a founder and past Chairperson of the Regulatory Sciences Section of the American Association of Pharmaceuticals Scientists, a member of the Dean's Advisory Board of the College of Pharmacy, University of Rhode Island, and a frequent contributor to industry-sponsored programs, committees, panel discussions and symposia. Dr. Motola received a Ph.D. in medicinal chemistry from the University of Rhode Island, College of Pharmacy, and is Regulatory Affairs Certified (RAC).